US 12,221,448 B2
Selective PI3Kδ inhibitor and use thereof
Qingsong Liu, Anhui (CN); Jing Liu, Anhui (CN); Xiaofei Liang, Anhui (CN); Feng Li, Anhui (CN); Ziping Qi, Anhui (CN); Zongru Jiang, Anhui (CN); Qingwang Liu, Anhui (CN); Kailin Yu, Anhui (CN); Zhenquan Hu, Anhui (CN); Beilei Wang, Anhui (CN); and Li Wang, Anhui (CN)
Assigned to TARAPEUTICS SCIENCE INC., Bengbu (CN)
Appl. No. 17/299,498
Filed by TARAPEUTICS SCIENCE INC., Bengbu (CN)
PCT Filed Dec. 12, 2018, PCT No. PCT/CN2018/120685
§ 371(c)(1), (2) Date Jun. 3, 2021,
PCT Pub. No. WO2020/113642, PCT Pub. Date Jun. 11, 2020.
Claims priority of application No. 201811471591.5 (CN), filed on Dec. 4, 2018.
Prior Publication US 2022/0024931 A1, Jan. 27, 2022
Int. Cl. C07D 487/04 (2006.01); A61P 19/02 (2006.01)
CPC C07D 487/04 (2013.01) [A61P 19/02 (2018.01)] 13 Claims
 
1. A kinase inhibitor, comprising a compound of formula (I) or a pharmaceutically acceptable salt or acid thereof:

OG Complex Work Unit Chemistry
wherein,
X is selected from the group consisting of CH and N;
R1 and R2 are each independently selected from the group consisting of hydrogen, halogen, and C1-6 haloalkyl;
R3 is C3-8 cycloalkyl;
R4 is selected from the group consisting of hydrogen and C1-6 alkyl;
R5 is selected from the group consisting of hydrogen, C1-6 alkyl, C1-6 alkoxy, C2-6 alkylamido, and C1-6 alkylaminoacyl;
R6 is selected from the group consisting of hydrogen, hydroxy, halogen, C1-6 alkyl, and C1-6 alkoxy;
or R5 and R6 together form a phenyl group or a dioxolane group.